Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 15INDUSTRY 4NIH 2NETWORK 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma 1Endometrial Neoplasms 1

Interventions

Cyclophosphamide 385Specimen Handling 370Magnetic Resonance Spectroscopy 325Radiotherapy 306Biopsy 269Cisplatin 257Carboplatin 253Paclitaxel 235Doxorubicin 226Fluorouracil 200Etoposide 197Vincristine 182Bevacizumab 180Filgrastim 170Gemcitabine 163Leucovorin 149Cytarabine 144aldesleukin 140Taxes 127Docetaxel 122Oxaliplatin 113Chemotherapy, Adjuvant 113fludarabine phosphate 111Rituximab 107Methotrexate 107Radiation 106Bortezomib 105Prednisone 102Irinotecan 100Dexamethasone 100

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Interventional × Medroxyprogesterone Acetate × Clear all
NCT03018249 2021-11-16

Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer

National Cancer Institute (NCI)

Phase EARLY_PHASE1 Completed
50 enrolled 12 charts
Gynecologic

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma

NCT00033358 2013-05-03

Hormone Therapy in Preventing Endometrial Cancer in Patients With a Genetic Risk For Hereditary Nonpolyposis Colon Cancer

National Cancer Institute (NCI)

Phase 2 Completed
52 enrolled
Gynecologic

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡